Abingworth Bioventures VII LP
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$240M
Investors
16
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Abingworth Bioventures VII LP is a United Kingdom limited partnership organized in 2016 that first filed a Form D on November 15, 2016 and most recently amended it on May 30, 2018, describing itself as a venture capital fund. The offering claims Rule 506(b), Section 3(c), Section 3(c)(7) and covers equity and pooled investment fund interests. Abingworth Bioventures VII LP reported $240,209,580 sold from 16 investors of a $400,000,000 total offering as of the Form D filed May 30, 2018. The filing states that the figure is combined across related vehicles, so it is not this entity's figure alone. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Asante Capital Group Advisors LLC (CRD 155178), associated with None; Asante Capital Group LLP, associated with None as recipients of sales compensation soliciting in all states. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is Princes House, 38 Jermyn Street, London, X0 SW1Y 6DN.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
0
none on file
Critical / warning
0 / 0
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
lapsed
Fund family Part of the Abingworth Bioventures family: 3 vehicles across 3 generations · full family and the filing behind each link in the terminal
Investor
- The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Adviser of Record (Form ADV)
CRD 157466 · lists this fund on Schedule D 7.B.(1) as a private equity fund
Auditor named on Form ADV: Deloitte LLP · PCAOB-registered per the adviser
From the adviser's Form ADV as loaded from the SEC bulk data through December 31, 2024, joined on this issuer's Form D file number. Fund-level figures and the adviser's full fund roster are in the terminal.
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
JAMES ABELL
Executive Officer · LONDON, X0
STEPHEN BUNTING
Executive Officer · LONDON, X0
TIMOTHY HAINES
Executive Officer · LONDON, X0
JOHN HEARD
Executive Officer · LONDON, X0
KURT VON EMSTER
Executive Officer · MENLO PARK, CA
GENGHIS LLOYD-HARRIS
Executive Officer · LONDON, X0
DAVID LEATHERS
Director · LONDON, X0
KENNETH HAAS
Promoter · MENLO PARK, CA
VINCENT MILES
Promoter · BOSTON, MA
SHELLEY CHU
Promoter · MENLO PARK, CA
MICHAEL BIGHAM
Promoter · BOSTON, MA
ABINGWORTH LLP
Promoter · LONDON, X0
Manager of the Issuer
ABINGWORTH BIOVENTURES VII GP LP
Promoter · EDINBURGH, X0
General Partner of the Issuer
ABINGWORTH MANAGEMENT INC
Promoter · MENLO PARK, CA
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Asante Capital Group Advisors LLCCRD 155178 on BrokerCheck
Associated broker-dealer: None · New York, NY · Soliciting in all states
Asante Capital Group LLP
Associated broker-dealer: None · London, X0 and outside the United States
Questions About Abingworth Bioventures VII LP
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Abingworth Bioventures VII LP?
Abingworth Bioventures VII LP is a United Kingdom limited partnership organized in 2016 that filed a Form D with the SEC on May 30, 2018 as a venture capital fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of equity and pooled investment fund interests.
Is Abingworth Bioventures VII LP legit?
AltStreet does not rate legitimacy; it reports the public record. Abingworth Bioventures VII LP filed a Form D with the SEC on May 30, 2018 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $240,209,580 sold to 16 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Abingworth Bioventures VII LP registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Abingworth Bioventures VII LP claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Abingworth Bioventures VII LP raised?
Abingworth Bioventures VII LP reported $240,209,580 sold from 16 investors of a $400,000,000 total offering as of the Form D filed May 30, 2018. The filing states that the figure is combined across related vehicles, so it is not this entity's figure alone.
Who can invest in Abingworth Bioventures VII LP?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in Abingworth Bioventures VII LP?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling Abingworth Bioventures VII LP and how are they paid?
The Form D names Asante Capital Group Advisors LLC (CRD 155178), associated with None; Asante Capital Group LLP, associated with None as recipients of sales compensation soliciting in all states. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.
Who is behind Abingworth Bioventures VII LP?
The Form D lists 14 related persons: JAMES ABELL, executive officer; STEPHEN BUNTING, executive officer; TIMOTHY HAINES, executive officer; JOHN HEARD, executive officer; KURT VON EMSTER, executive officer; GENGHIS LLOYD-HARRIS, executive officer; DAVID LEATHERS, director; KENNETH HAAS, promoter, and 6 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Abingworth Bioventures VII LP located?
The issuer's address on its SEC filings is Princes House, 38 Jermyn Street, London, X0 SW1Y 6DN. Its phone number of record is 44 207 534 1500. It is organized under the laws of United Kingdom.
How long is the Abingworth Bioventures VII LP offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 2 amendments are on record for this CIK.
How large is Abingworth Bioventures VII LP?
The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.